DermTech Adds $5.6M For Skin Cancer Detection

San Diego-based DermTech, a biotechnology company which is developing technology for detecting skin cancer, has raised $5.6M in a Series B funding. The funding was led by Jacobs Investment COmpany, and also included other, un-named investors. According to DermTech, the funds will go towards further development and laboratory accreditation efforts. DermTech is commercializing qPCR (quantitative polymerase chain reaction) assays for skin samples, to identify gene targets to detect melanoma. More information »